- Home
- CHRS vs GPRO Comparison
CHRS vs GPRO Comparison
Compare CHRS & GPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- GPRO
- Stock Information
- Founded
- CHRS 2010
- GPRO 2004
- Country
- CHRS United States
- GPRO United States
- Employees
- CHRS N/A
- GPRO N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- GPRO Industrial Machinery/Components
- Sector
- CHRS Health Care
- GPRO Consumer Discretionary
- Exchange
- CHRS Nasdaq
- GPRO Nasdaq
- Market Cap
- CHRS 191.3M
- GPRO 193.5M
- IPO Year
- CHRS 2014
- GPRO 2014
- Fundamental
- Price
- CHRS $1.37
- GPRO $1.08
- Analyst Decision
- CHRS Strong Buy
- GPRO Hold
- Analyst Count
- CHRS 4
- GPRO 1
- Target Price
- CHRS $5.38
- GPRO $1.50
- AVG Volume (30 Days)
- CHRS 1.9M
- GPRO 1.4M
- Earning Date
- CHRS 03-12-2025
- GPRO 02-06-2025
- Dividend Yield
- CHRS N/A
- GPRO N/A
- EPS Growth
- CHRS N/A
- GPRO N/A
- EPS
- CHRS N/A
- GPRO N/A
- Revenue
- CHRS $304,340,000.00
- GPRO $896,011,000.00
- Revenue This Year
- CHRS $2.47
- GPRO N/A
- Revenue Next Year
- CHRS N/A
- GPRO N/A
- P/E Ratio
- CHRS N/A
- GPRO N/A
- Revenue Growth
- CHRS 44.19
- GPRO N/A
- 52 Week Low
- CHRS $0.66
- GPRO $1.03
- 52 Week High
- CHRS $2.87
- GPRO $3.40
- Technical
- Relative Strength Index (RSI)
- CHRS 49.80
- GPRO 47.76
- Support Level
- CHRS $1.31
- GPRO $1.03
- Resistance Level
- CHRS $1.60
- GPRO $1.19
- Average True Range (ATR)
- CHRS 0.12
- GPRO 0.04
- MACD
- CHRS -0.03
- GPRO 0.01
- Stochastic Oscillator
- CHRS 28.00
- GPRO 51.61
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About GPRO GoPro Inc.
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.